## Abstract A C3H murine osteosarcoma was used to investigate the effects of surgical adjuvant chemotherapy and to establish the relationship between primary tumor size and the number of metastatic lung tumor foci. The transplanted primary tumor was allowed to grow for 28 or 33 days and the lungs w
Chemotherapy and surgery in a murine osteosarcoma
β Scribed by Dr. R. S. Bell; J. Jacobs
- Publisher
- Elsevier Science
- Year
- 1992
- Tongue
- English
- Weight
- 821 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0736-0266
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Surgical and chemotherapeutic effects on pulmonary metastatic disease were evaluated in the MGHβOGS murine osteosarcoma. The tumor responded to three sequential injections of doxorubicin with prolonged growth delay but cisplatin administration (although given in doses sufficient to cause weight loss and significant mortality) was not effective in controlling local disease progression. Using a protocol with three injections of doxorubicin (0.006 mg/g of body weight), it was observed that diseaseβfree survival was enhanced when one of the three doses of doxorubicin was given at the time of surgery (perioperatively). By marginally resecting the primary tumor and permitting its regrowth, a model was developed with recurrent primary and metastic disease present simultaneously. It was observed in this model that amputation or resection of the recurrent primary lesion resulted in pulmonary metastatic growth acceleration. Using this recurrent primary tumor model, doxorubicin's effect on pulmonary metastatic lesions was enhanced when the drug was given at the time of amputation.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Contemporary therapy for osteosarcoma is comprised of initial treatment with chemotherapy and surgical extirpation of the primary tumor in the affected bone. In view of the major advances forged by chemotherapy in the treatment of the primary tumor, an attempt was made to
## Abstract The C1300 murine neuroblastoma system has been studied to determine its relevance as a chemotherapy model to the human disease. Studies using combination therapy revealed that BCNU/cyclophosphamide combination therapy increased the median lifespan 300% in A/J mice bearing the C1300 tumo
## Abstract This report updates experience with the CONPADRIβI, COMPADRIβII, and COMPADRIβIII adjuvant chemotherapy programs for the treatment of nonmetastatic osteosarcoma. A total of 200 patients received one of the three regimens. The analysis of response to treatment is based on diseaseβfree su